

SUPPORTING INFORMATION

Perfluorinated Alkyl Acids in Blood Serum from Primiparous Women in Sweden: Serial Sampling during Pregnancy and Nursing, and Temporal Trends 1996-2010

Anders Glynn,^{†,*} Urs Berger,[‡] Anders Bignert,[§] Shahid Ullah,[‡] Marie Aune,[†] Sanna Lignell,[†] Per Ola Darnerud[†]

[†] Department of Research and Development, National Food Agency, P.O. Box 622, SE-751 26 Uppsala, Sweden

[‡] Department of Applied Environmental Science (ITM), Stockholm University, SE-106 91 Stockholm, Sweden

[§] Department of Contaminant Research, Swedish Museum of Natural History, SE-104 05 Stockholm, Sweden

*Corresponding author phone: int+46 18 175634; fax: int+46 18 105848; e-mail:
anders.glynn@slv.se

Table S1. Composition of the pooled serum samples in the temporal trend study.

Table S2. Analytical standard compounds used in the present study and selected instrumental parameters.

Table S3. Linear regression (r^2 values) and residuals for the solvent based calibration curves.

Table S4. Compound specific method detection (MDLs) and quantification limits (MQLs) of perfluorinated substances in human serum samples as well as mean recovery \pm relative standard error ($n=3$) from spiked (2 ng/g) serum and whole blood samples.

Table S5. Mean recovery \pm relative standard error for all internal standards in the temporal trend study ($n=36$) and for $^{13}\text{C}_4\text{-PFOA}$ and $^{13}\text{C}_4\text{-PFOS}$ in the serial samples study ($n=95$). The spike concentration was 10 ng/g.

Table S6. Levels of PFAAs and FOSA [ng/g] in pooled samples of blood serum from nursing women 3 weeks after delivery.

Table S1. Composition of the pooled serum samples in the temporal trend study.^a

| year (N) | no. of pools | N in each pool | age (years, mean±SD) |
|-----------|--------------|----------------|----------------------|
| 1996 (19) | 3 | 6-7 | 30±5 |
| 1997 (62) | 3 | 20-21 | 28±4 |
| 1998 (74) | 3 | 24-25 | 29±4 |
| 1999 (17) | 3 | 5-6 | 27±3 |
| 2000 (20) | 2 | 10 | 30±4 |
| 2001 (9) | 1 | 9 | 29±5 |
| 2002 (31) | 3 | 10-11 | 30±3 |
| 2004 (32) | 3 | 10-11 | 29±4 |
| 2006 (30) | 3 | 10 | 30±4 |
| 2007 (29) | 3 | 9-10 | 30±5 |
| 2008 (30) | 3 | 10 | 29±5 |
| 2009 (30) | 3 | 10 | 29±4 |
| 2010 (30) | 3 | 10 | 30±5 |

^a Blood serum was sampled from primiparous women 3 weeks after delivery.

Table S2. Analytical standard compounds used in the present study and selected instrumental parameters.

| Compound | Acronym | Obtained as | Supplier | Triple quadrupole MS/MS | | | Q-ToF-HRMS | |
|------------------------------------------------------------------------------------|--------------------------------------|-----------------|-------------------------|-------------------------|------------------------------------|-----------------------|------------------|---------------------------|
| | | | | Cone voltage [V] | MRM precursor → product mass [m/z] | Collision energy [eV] | Cone voltage [V] | Quantification mass [m/z] |
| Perfluorobutane sulfonate | PFBS | Potassium salt | Wellington | | | | 50 | 298.94 |
| Perfluorohexane sulfonate | PFHxS | Sodium salt | mixture | | | | 50 | 398.94 |
| Perfluoroctane sulfonate ^a | PFOS | Sodium salt | PFS-MXA ^b | 52 | 499 → 80+99 | 77 | 50 | 498.93 |
| Perfluorodecane sulfonate | PFDS | Sodium salt | | | | | 50 | 598.92 |
| Perfluoroctane sulfonamide | FOSA | - | Wellington ^b | | | | 50 | 497.95 |
| Perfluorohexanoate | PFHxA | Carboxylic acid | | | | | 20 | 268.98 |
| Perfluoroheptanoate | PFHpA | Carboxylic acid | | | | | 20 | 318.98 |
| Perfluoroctanoate | PFOA | Carboxylic acid | | 20 | 413 → 369 | 10 | 20 | 368.98 |
| Perfluorononanoate | PFNA | Carboxylic acid | Wellington | 20 | 463 → 419 | 12 | 20 | 418.97 |
| Perfluorodecanoate | PFDA | Carboxylic acid | mixture | | | | 20 | 468.97 |
| Perfluoroundecanoate | PFUnDA | Carboxylic acid | PFC-MXA ^b | | | | 20 | 518.97 |
| Perfluorododecanoate | PFDoDA | Carboxylic acid | | | | | 20 | 568.96 |
| Perfluorotridecanoate | PFTrDA | Carboxylic acid | | | | | 20 | 618.96 |
| Perfluorotetradecanoate | PFTeDA | Carboxylic acid | | | | | 20 | 668.96 |
| ¹⁸ O ₂ -Perfluoro- <i>n</i> -hexane sulfonate ^c | ¹⁸ O ₂ -PFHxS | Sodium salt | | | | | 50 | 402.93 |
| ¹³ C ₄ -Perfluoro- <i>n</i> -octane sulfonate ^{c,d} | ¹³ C ₄ -PFOS | Sodium salt | | 52 | 503 → 80 | 77 | 50 | 502.93 |
| ¹³ C ₂ -Perfluoro- <i>n</i> -hexanoate ^c | ¹³ C ₂ -PFHxA | Carboxylic acid | | | | | 20 | 269.99 |
| ¹³ C ₄ -Perfluoro- <i>n</i> -octanoate ^{c,d} | ¹³ C ₄ -PFOA | Carboxylic acid | Wellington | 20 | 417 → 372 | 10 | 20 | 371.98 |
| ¹³ C ₅ -Perfluoro- <i>n</i> -nonanoate ^c | ¹³ C ₅ -PFNA | Carboxylic acid | mixture | | | | 20 | 422.98 |
| ¹³ C ₂ -Perfluoro- <i>n</i> -decanoate ^c | ¹³ C ₂ -PFDA | Carboxylic acid | MPFAC-MXA ^b | | | | 20 | 469.98 |
| ¹³ C ₂ -Perfluoro- <i>n</i> -undecanoate ^c | ¹³ C ₂ -PFUnDA | Carboxylic acid | | | | | 20 | 519.97 |
| ¹³ C ₂ -Perfluoro- <i>n</i> -dodecanoate ^c | ¹³ C ₂ -PFDoDA | Carboxylic acid | | | | | 20 | 569.97 |
| ¹³ C ₈ -Perfluoro- <i>n</i> -octane sulfonate ^e | ¹³ C ₈ -PFOS | Sodium salt | Wellington ^b | 52 | 507 → 80 | 77 | 50 | 506.93 |
| ¹³ C ₈ -Perfluoro- <i>n</i> -octanoate ^e | ¹³ C ₈ -PFOA | Carboxylic acid | Wellington ^b | 20 | 421 → 376 | 10 | 20 | 375.98 |

^a A technical PFOS standard from Fluka (Buchs, Switzerland) was applied in MS/MS^c Used as internal (surrogate) standard^b Wellington, Guelph, ON, Canada^e Used as volumetric standard

Table S3. Linear regression (r^2 values) and residuals for the solvent based calibration curves.^a

| | PFHxA | PFHpA | PFOA | PFNA | PFDA | PFUnDA | PFDoDA | PFTrDA | PFTeDA |
|----------------------|--------------|--------------|-------------|-------------|-------------|---------------|---------------|---------------|---------------|
| r² | 0.9991 | 0.9994 | 0.9992 | 0.9997 | 0.9989 | 0.9998 | 0.9986 | 0.9995 | 0.9992 |
| residuals | <12% | <14% | <9% | <8% | <15% | <8% | <7% | <13% | <12% |
| PFBS | PFHxS | PFOS | PFDS | FOSA | | | | | |
| r² | 0.9990 | 0.9999 | 0.9998 | 0.9996 | 0.9999 | | | | |
| residuals | <15% | <6% | <8% | <11% | <12% | | | | |

^a Five concentrations included from the individual quantification limits to 5 ng/mL.

Table S4. Compound specific method detection (MDLs) and quantification limits (MQLs) of perfluorinated substances in human serum samples as well as mean recovery \pm relative standard error ($n=3$) from spiked (2 ng/g) serum and whole blood samples.

| | Triple quad. MS/MS | | Q-ToF-HRMS | | Recovery ^a | |
|---------------|--------------------|---------------|---------------|---------------|-------------------------|--------------------|
| | MDL [ng/g] | MQL [ng/g] | MDL [ng/g] | MQL [ng/g] | Serum [%] | Whole blood [%] |
| PFHxA | | | 0.05 | 0.15 | 80 \pm 4 | 72 \pm 6 |
| PFHpA | | | 0.05 | 0.15 | 78 \pm 2 | 83 \pm 4 |
| PFOA | 0.15 | 0.42 | 0.035 | 0.1 | 84 \pm 5 ^b | 81 \pm 3 |
| PFNA | 0.05 | 0.16 | 0.03 | 0.1 | 90 \pm 2 | 89 \pm 5 |
| PFDA | | | 0.07 | 0.2 | 93 \pm 6 | 87 \pm 5 |
| PFUnDA | | | 0.05 | 0.15 | 92 \pm 3 | 83 \pm 4 |
| PFDoDA | | | 0.1 | 0.3 | 90 \pm 3 | 84 \pm 4 |
| PFTrDA | | | 0.15 | 0.45 | 81 \pm 4 | 75 \pm 6 |
| PFTeDA | | | 0.25 | 0.7 | 72 \pm 5 | 68 \pm 5 |
| PFBS | | | 0.013 | 0.03 | 77 \pm 4 | 83 \pm 4 |
| PFHxS | | | 0.007 | 0.02 | 81 \pm 2 ^b | 82 \pm 3 |
| PFOS | 0.2 | 0.57 | 0.008 | 0.025 | 83 \pm 4 ^c | 86 \pm 3 |
| PFDS | | | 0.01 | 0.03 | 76 \pm 5 | 80 \pm 5 |
| FOSA | | | 0.04 | 0.1 | 77 \pm 3 | 78 \pm 2 |

^a Calculated after subtraction of endogenous PFAS concentrations.

^b Uncertain estimations due to the relatively high endogenous concentrations (PFOA 2.3 ng/g and PFHxS 1.4 ng/g quantified) compared to the spiked concentrations of 2 ng/g.

^c A spiking level of 20 ng/g was used for PFOS due to the high endogenous concentrations (24.2 ng/g quantified).

Table S5. Mean recovery \pm relative standard error for all internal standards in the temporal trend study ($n=36$) and for $^{13}\text{C}_4\text{-PFOA}$ and $^{13}\text{C}_4\text{-PFOS}$ in the serial samples study ($n=95$). The spike concentration was 10 ng/g.

| | $^{13}\text{C}_2\text{-PFHxA}$ | $^{13}\text{C}_4\text{-PFOA}$ | $^{13}\text{C}_5\text{-PFNA}$ | $^{13}\text{C}_2\text{-PFDA}$ | $^{13}\text{C}_2\text{-PFUnDA}$ | $^{13}\text{C}_2\text{-PFDoDA}$ | $^{18}\text{O}_2\text{-PFHxS}$ | $^{13}\text{C}_4\text{-PFOS}$ |
|-----------------------------------------|--------------------------------|-------------------------------|-------------------------------|-------------------------------|---------------------------------|---------------------------------|--------------------------------|-------------------------------|
| Recovery [%] ($n=36$) | 78 \pm 3 | 84 \pm 1 | 92 \pm 1 | 86 \pm 2 | 88 \pm 1 | 83 \pm 2 | 84 \pm 0.6 | 81 \pm 2 |
| Recovery [%] ($n=95$) | | 84 \pm 0.8 | | | | | 80 \pm 1 | |

Table S6. Levels of PFAAs and FOSA [ng/g] in pooled samples of blood serum from nursing women 3 weeks after delivery.^a

| Year | PFBS | PFHxS | PFOS | PFDS | FOSA | PFHpA | PFOA | PFNA | PFDA | PFUnDA |
|-------------|--------------|-------|------|--------------|--------|--------------|------|-------|--------------|--------------|
| 1996 | <0.013 | 1.61 | 22.7 | 0.137 | 0.793 | 0.075 | 2.18 | 0.468 | 0.159 | 0.189 |
| 1996 | <i>0.014</i> | 2.44 | 27.3 | 0.042 | 0.572 | <i>0.078</i> | 2.92 | 0.386 | <i>0.186</i> | 0.212 |
| 1996 | <i>0.021</i> | 2.24 | 23.3 | 0.260 | 0.507 | <i>0.084</i> | 2.69 | 0.502 | 0.211 | 0.163 |
| 1997 | <i>0.028</i> | 2.30 | 24.8 | <i>0.089</i> | 0.610 | <i>0.100</i> | 3.07 | 0.375 | 0.231 | 0.228 |
| 1997 | <0.013 | 1.55 | 20.3 | 0.153 | 0.602 | <i>0.114</i> | 2.26 | 0.258 | 0.221 | 0.154 |
| 1997 | <0.013 | 1.63 | 20.7 | 0.148 | 0.441 | <i>0.080</i> | 2.54 | 0.439 | 0.234 | 0.261 |
| 1998 | <0.013 | 1.16 | 20.2 | <i>0.021</i> | 0.477 | <i>0.073</i> | 2.22 | 0.393 | 0.198 | 0.168 |
| 1998 | <0.013 | 1.99 | 23.1 | 0.166 | 0.410 | <i>0.140</i> | 2.66 | 0.438 | 0.226 | 0.223 |
| 1998 | <i>0.019</i> | 2.19 | 21.0 | 0.044 | 0.514 | <i>0.084</i> | 2.35 | 0.411 | 0.209 | 0.202 |
| 1999 | <0.013 | 2.00 | 20.0 | <i>0.020</i> | 0.512 | <i>0.061</i> | 2.38 | 0.311 | <i>0.136</i> | 0.153 |
| 1999 | <0.013 | 2.95 | 21.5 | 0.046 | 0.584 | <i>0.056</i> | 3.11 | 0.404 | <i>0.152</i> | 0.262 |
| 1999 | <i>0.013</i> | 1.80 | 23.0 | <i>0.022</i> | 0.572 | <i>0.118</i> | 2.49 | 0.387 | <i>0.173</i> | <i>0.144</i> |
| 2000 | <i>0.018</i> | 2.40 | 18.7 | 0.048 | 0.363 | <i>0.063</i> | 2.65 | 0.353 | <i>0.173</i> | 0.198 |
| 2000 | <0.013 | 3.03 | 22.0 | 0.052 | 0.441 | <i>0.094</i> | 2.50 | 0.384 | <i>0.172</i> | 0.201 |
| 2001 | <i>0.017</i> | 1.96 | 28.1 | 0.057 | 0.572 | <i>0.110</i> | 3.05 | 0.609 | 0.264 | 0.320 |
| 2002 | <i>0.024</i> | 2.25 | 17.0 | 0.064 | 0.185 | <i>0.079</i> | 2.17 | 0.353 | <i>0.182</i> | 0.228 |
| 2002 | <i>0.016</i> | 3.04 | 18.7 | 0.037 | 0.282 | <i>0.132</i> | 2.59 | 0.469 | 0.223 | 0.272 |
| 2002 | <0.013 | 2.87 | 23.2 | 0.048 | 0.301 | <i>0.087</i> | 2.98 | 0.493 | 0.267 | 0.274 |
| 2004 | <i>0.028</i> | 2.16 | 16.0 | 0.037 | 0.073 | <i>0.102</i> | 2.12 | 0.497 | 0.261 | 0.303 |
| 2004 | <i>0.025</i> | 3.82 | 16.6 | 0.051 | 0.205 | <i>0.097</i> | 2.12 | 0.474 | 0.295 | 0.299 |
| 2004 | <0.013 | 1.85 | 13.6 | 0.052 | 0.105 | <i>0.107</i> | 2.15 | 0.431 | 0.285 | 0.180 |
| 2006 | 0.067 | 3.87 | 16.5 | 0.043 | 0.101 | <i>0.089</i> | 2.11 | 0.573 | 0.277 | 0.240 |
| 2006 | 0.042 | 5.26 | 12.2 | <i>0.026</i> | <0.040 | <i>0.093</i> | 1.89 | 0.432 | 0.245 | 0.175 |
| 2006 | 0.032 | 3.24 | 10.7 | <i>0.025</i> | <0.040 | <i>0.080</i> | 1.70 | 0.417 | 0.253 | 0.241 |
| 2007 | 0.036 | 4.48 | 15.1 | 0.057 | 0.071 | <i>0.090</i> | 2.41 | 0.755 | 0.289 | 0.245 |
| 2007 | 0.033 | 4.68 | 18.3 | <i>0.022</i> | 0.078 | <i>0.065</i> | 2.42 | 0.553 | 0.287 | 0.225 |
| 2007 | <i>0.025</i> | 3.20 | 8.80 | <i>0.023</i> | 0.056 | <i>0.064</i> | 1.36 | 0.503 | 0.200 | 0.185 |
| 2008 | 0.051 | 5.05 | 11.1 | <i>0.021</i> | <0.040 | <i>0.114</i> | 2.01 | 0.798 | <i>0.190</i> | 0.208 |
| 2008 | 0.060 | 3.92 | 9.25 | <i>0.024</i> | 0.049 | <i>0.058</i> | 1.69 | 0.499 | 0.275 | 0.254 |
| 2008 | 0.064 | 4.12 | 10.4 | 0.039 | <0.040 | <i>0.082</i> | 2.58 | 0.866 | 0.386 | 0.262 |
| 2009 | 0.082 | 4.00 | 7.14 | <i>0.023</i> | <0.040 | <i>0.056</i> | 1.54 | 0.450 | 0.352 | 0.281 |
| 2009 | 0.054 | 4.58 | 8.68 | <i>0.019</i> | <0.040 | <i>0.086</i> | 2.40 | 0.783 | 0.329 | 0.247 |
| 2009 | 0.091 | 5.95 | 8.89 | 0.035 | <0.040 | <i>0.107</i> | 1.80 | 0.722 | 0.288 | 0.285 |
| 2010 | 0.070 | 5.83 | 7.61 | <i>0.025</i> | <0.040 | <i>0.112</i> | 1.96 | 0.857 | 0.421 | 0.311 |
| 2010 | 0.092 | 5.63 | 5.11 | <i>0.011</i> | <0.040 | <i>0.073</i> | 1.71 | 0.701 | 0.299 | 0.232 |
| 2010 | 0.101 | 7.95 | 7.62 | <i>0.014</i> | <0.040 | <i>0.082</i> | 1.39 | 0.589 | 0.276 | 0.188 |

^a PFAAs with levels below the method detection limit (MDL) in all samples: PFHxA (<0.05 ng/g serum), PFDoDA (<0.1 ng/g), PFTrDA (<0.15 ng/g) and PFTeDA (<0.25 ng/g). Data in italics are above MDL but below the method quantification limit. For information about number of individual samples in each pool see Table S1.